产品简要
公司名称 :
ACROBiosystems
产品类型 :
蛋白
产品名称 :
Human NOTCH1 Protein, Fc Tag (MALS verified)
目录 :
NO1-H5255
规格 :
1毫克, 100微克
价格 :
2310美元, 350美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
蛋白
目录 :
NO1-H5255
产品名称 :
Human NOTCH1 Protein, Fc Tag (MALS verified)
规格 :
1毫克, 100微克
价格 :
2310美元, 350美元
规格&价格 :
$350/100ug,$2310/1mg (250ug × 4)
靶标 :
NOTCH1
宿主物种 :
人类
By Tag :
Fc标签
研究 :
For Research Use Only
来源 :
Human NOTCH1, Fc Tag (NO1-H5255) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - Gln 526 (Accession # P46531-1).
内毒素 :
Less than 1.0 EU per μg by the LAL method.
纯度 :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human NOTCH1, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
配方 :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
重组 :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
储存 :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
背景 :
NOTCH1 Interacts with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also interacts with MAML1, MAML2 and MAML3 which act as transcriptional coactivators for NOTCH1. The NOTCH1 intracellular domain interacts with SNW1; the interaction involves multimerized NOTCH1 NICD and is implicated in a formation of an intermediate preactivation complex which associates with DNA-bound CBF-1/RBPJ. The activated membrane-bound form interacts with AAK1 which promotes NOTCH1 stabilization. Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Involved in the maturation of both CD4+ and CD8+ cells in the thymus. Important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, functions as a receptor for neuronal DNER and is involved in the differentiation of Bergmann glia.
参考文献 :
(1) Wu L, et.al. Nat Genet. 2000. 26(4):484-9.
(2) Wu L, et.al. Mol Cell Biol. 2002. 22(21):7688-700.
(3) Zhou S, et al. Mol Cell Biol. 2000. 20(7):2400-10.
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.